Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rotavirus vaccine, live, oral, pentavalent (Merck & Co., 0455e2)
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The pentavalent rotavirus vaccine (PRV) is a live-attenuated, oral vaccine designed to prevent severe gastroenteritis caused by rotavirus infection in infants and young children. It typically consists of five human-bovine reassortant rotavirus strains, each carrying a different human rotavirus surface protein (VP7 or VP4) representing the most common global serotypes (e.g., G1, G2, G3, G4, and G9 or P[8]). By mimicking natural infection without causing disease, the vaccine induces mucosal and systemic immunity, significantly reducing the incidence of rotavirus-related hospitalizations and deaths. Major versions include Merck's RotaTeq and the Serum Institute of India's ROTASIIL, the latter of which was developed in collaboration with PATH to provide a more affordable and heat-stable option for low- and middle-income countries.
- Brand names
- RotaTeqROTASIIL
- Other names
- PRVpentavalent rotavirus vaccine (bovine-human reassortant)rotavirus vaccine, live, oral, pentavalent
02
Targets
VP4 (Rotavirus VP4)VP7 (Rotavirus A VP7 outer capsid glycoprotein)RVA (Rotavirus A)
Beyond the preview
Go deeper on rotavirus vaccine, live, oral, pentavalent (Merck & Co., 0455e2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rotavirus vaccine, live, oral, pentavalent (Merck & Co., 0455e2).